Medical/Pharmaceuticals
Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026
BEIJING, Oct. 14, 2026 /PRNewswire/ -- Likang Life Sciences will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026, to be held October 20–22 at the ADNEC Centre in Abu Dhabi, the United Arab Emirates. Shannon Cheung, Co-Founder and Vice Chairman of Likang, will join a pa...
2026-10-14 10:25
2636
Osara Health and Medibank partner to bring one-on-one cancer coaching to members
From 14 October, eligible Medibank members living with cancer can access Osara Health's Cancer Coach program for personalised support with the physical and emotional challenges of diagnosis and treatment. SYDNEY, Oct. 14, 2026 /PRNewswire/ -- Osara Health has partnered with Medibank, one of Aust...
2026-10-14 05:11
2862
Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)
SD-101 (Zorblesia™) is the First Topical Therapy Developed to Treat Wounds and Lesions Across the Entire Skin Surface of All Epidermolysis Bullosa (EB) Subtypes This second consecutive nomination places our company and focus on Epidermolysis Bullosa among a select group of visionaries shaping th...
2026-10-14 04:20
2828
Datasea's Five AI Agent Customer Arrangements Reach Approximately US$4.0 Million in Aggregate Service Value
Aggregate service value increased approximately 264% from the approximately US$1.10 million disclosed in mid-September; continued execution advances AI agent commercialization under arrangements previously disclosed with potential annualized service volume of up to approximately US$89.4 million ...
2026-10-13 21:30
5789
AI-driven Molecular Glue Innovation: Insilico Nominates ISM9546, an Oral, Peripheral-Restricted VAV1 Degrader as PCC for Autoimmune Diseases
* Sustained Boost in AI-Driven R&D Productivity: ISM9546 marks Insilico Medicine's 35th preclinical candidate (PCC) nominated since 2021 and its 11th PCC within the first 10 months of 2026 alone, setting a new record for the company's annual pipeline output efficiency. * AI-Enabled Molecular ...
2026-10-13 21:00
4078
Ailux Appoints Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer
* Dr. Miller will lead the advancement of the company's AI-native biologics toward first-in-human trials, with initial clinical entry targeted for 2027 * He will also establish a U.S. clinical and research site to complement the company's research capabilities in Shanghai and the U.K. SHANGHAI...
2026-10-13 20:00
3170
Kelun-Biotech to Present Multiple Study Results at ESMO 2026
CHENGDU, China, Oct. 13, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) will present results from multiple clini...
2026-10-13 19:23
2892
Hiteck Licenses Investigational Next-Generation NGF Eye Drop HT006.2.2 to Visara for Neurotrophic Keratitis Outside Greater China
Hiteck grants Visara, a majority-owned ophthalmology subsidiary of NovaBridge Biosciences (NASDAQ: NBP), exclusive worldwide rights, excluding Greater China, to develop and commercialize HT006.2.2 Hiteck retains all rights in Greater China, where a Phase 1b study in severe neurotrophic keratitis...
2026-10-13 19:00
2924
ELEHEAR Earns Two 2026 Hearing Technology Innovator Awards™ from Hearing Health & Technology Matters
Beyond 2 Pro and ElePro® Plus awarded industry recognition as ELEHEAR continues
its mission to make personalized hearing care more accessible
CHICAGO, Oct. 13, 2026 /PRNewswire/ -- ELEHEAR
2026-10-13 19:00
2353
The Right Doctor Isn't Always One Doctor
Why complex brain and spine conditions increasingly call for specialists to work across disciplines. KUALA LUMPUR, Malaysia, Oct. 13, 2026 /PRNewswire/ -- When faced with a brain, spine or neurological condition, one of the first questions a patient or family member may ask is: Which doctor sh...
2026-10-13 16:15
1773
Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases
SANTA BARBARA, Calif., Oct. 13, 2026 /PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary ext...
2026-10-13 15:00
6962
World Thrombosis Day campaign urges global action to protect women against blood clots
Global campaign brings together partners to raise awareness of women's unique blood clot risks, recognize warning signs and take action to prevent life-threatening events. CHARLOTTE, N.C., Oct. 13, 2026 /PRNewswire/ -- One in four people worldwide die from conditions caused by thrombosis, yet bl...
2026-10-13 14:00
2264
ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention
SHANGHAI, Oct. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company...
2026-10-13 09:00
3358
GCCL and LabConnect Sign MOU to Expand Global Clinical Trial Collaboration
Linking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution SEOUL, South Korea and RALEIGH, N.C., Oct. 13, 2026 /PRNewswire/ -- GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today that i...
2026-10-13 08:15
3639
SPARX Global Randomized Controlled Trial by Translumina Initiated to Advance Evidence for Drug-Coated Balloons in Complex Coronary Disease
LUCERNE, Switzerland and NEW DELHI, Oct. 13, 2026 /PRNewswire/ -- The SPARX Global Randomized Controlled Trial (RCT) has been officially initiated, marking the launch of the multinational randomized trial evaluating a drug-coated balloon (DCB)-first strategy against contemporary drug-eluting sten...
2026-10-13 02:11
3442
Fair2Care: Canton Fair Launches International Medical Experience for the First Time
GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- The 140th Canton Fair will open on October 15 with a brand-new experience for attendees. For the first time, the Fair is introducing an exclusive Fair2Care International Medical Experience Program. The program features a dual experience model that c...
2026-10-12 21:01
3085
Lunit and Discovery Life Sciences Collaborate to Expand AI-Powered Tissue Analysis for Biopharma Research
Collaboration expands access to Lunit's AI-powered pathology platform by combining it with Discovery Life Sciences' global biospecimen and specialty laboratory capabilities, enabling standardized tissue insights for biomarker research and drug development. SEOUL, South Korea, Oct. 12, 2026 /PRNe...
2026-10-12 21:00
2798
POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare
GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solutions, today highlighted its strategy to participate in the ongoing transformatio...
2026-10-12 20:00
1783
T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer
BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T therapy, for ...
2026-10-12 18:50
2209
CLASSYS Appoints Former Bain & Company Partner Jung-hee Bae as Chief Commercial Officer to Accelerate Global Expansion
SEOUL, South Korea, Oct. 12, 2026 /PRNewswire/ -- CLASSYS Inc. (KOSDAQ: 214150), a global medical aesthetics platform company, announced today that it has established the position of Chief Commercial Officer (CCO) and appointed Jung-hee Bae, a former Bain & Company partner, as Vice President, CCO...
2026-10-12 18:02
4025
Week's Top Stories
Most Reposted
TD Brings its Global Asset Management Businesses Under One Name
[Picked up by 1169 media titles]
2026-11-02 20:00OceanaGold Reports Third Quarter 2026 Results
[Picked up by 1130 media titles]
2026-11-05 06:52Algolia Powers Orange with AI Agents for Billing Support: NYSE Content Update
[Picked up by 1118 media titles]
2026-11-06 22:06
Overstory Launches Integrated AI Platform to Deliver First Living Model of Grid Risk
[Picked up by 1082 media titles]
2026-11-03 22:00NYSE Chair Sharon Bowen Earns Lifetime Achievement Award: NYSE Content Update
[Picked up by 1073 media titles]
2026-11-05 22:05
Most Read
Airbrush Upgrades AI Image Enhancer With 16K Output and Batch Processing for Up to 50 Images
2026-11-03 02:00
62481
Korean Derma Skincare Brand MDP+ Launches at Nordstrom
2026-11-03 00:30
27852
Home Companion Robot Mobo to Debut Globally and Open Pre-orders as AiMOGA Showcases Its Robot Family at the 2026 OMODA & JAECOO International User Summit
2026-11-07 13:49
21630
Lorikeet Dreamweaver enables businesses to give every customer an AI account manager
2026-11-04 22:00
18942